Gilead Sciences' (GILD) Price Target Bumped to $135 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'
July 29, 2015 9:10 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) to $134.00 (from $131.00) following another 'beat and raise'.
Schimmer commented, "GILD hosted its 2Q earnings call after the close and again easily beat consensus product... More
Gilead Sciences (GILD) PT Lifted to $135 at Baird on Strong Earnings Beat
July 29, 2015 6:58 AM EDTBaird analyst Brian Skorney lifted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $135.00 (from $126.00) following earnings beat.
Skorney commented, "Gilead handily beat expectations, across the board, and raised revenue guidance yet again. Interestingly, nothing in Hep C declined... More
Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat
July 29, 2015 6:28 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $86.00) following solid the Q2 beat.
Lam commented, "GILD reported a healthy 2Q15 EPS and product revenues beat ($3.15/$8.13B vs. $2.71/$7.60B consensus) underpinned by... More
Gilead Sciences (GILD) Tops Q2 EPS by 44c
July 28, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.15, $0.44 better than the analyst estimate of $2.71. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $7.61 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More